Moderna Beats Expectations, Posts Revenue Growth in Q2

MRNA reported second-quarter revenue of $145 million, up 2% year over year and above the high end of its own guidance. The net loss narrowed to $782 million, or $1.97 per share, from $825 million, or $2.13 per share, a year earlier. Against expectations the quarter was a beat, and the stock still slipped.

The reason sits outside the income statement. Moderna's norovirus vaccine candidate mRNA-1403 failed to meet interim efficacy criteria in its Phase 3 trial, removing a pipeline asset investors had been assigning value to. The company also took a roughly $0.9 billion litigation charge, with a $950 million cash payment made in July, which weighs on a balance sheet already funding an expensive pipeline against a shrinking commercial base.

Management reaffirmed its 2026 outlook of up to 10% revenue growth, excluding flu and COVID-flu combination products, and improved both operating expense and cash cost guidance by $200 million each. That cost discipline is the clearest positive in the print: Moderna is extending runway while it waits for pipeline assets to mature.

The investment question is unchanged and now slightly harder. Revenue at $145 million a quarter is a fraction of the pandemic-era base, so the equity value rests on pipeline conversion rather than current cash generation. Each Phase 3 disappointment compresses the number of shots on goal. Watch cash burn against the improved cost guidance, the respiratory franchise's autumn season, and the next set of Phase 3 readouts.

Related Stocks

• MRNA